Mantle Cell Lymphoma REVIEW ARTICLE

Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older patients. In particular, greater depth of understanding of the molecular pathophysiology of MCL has resulted in an explosion of specifically targeted new efficacious agents. In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton’s tyrosine kinase inhibitor ibrutinib. We review recent advances in the understanding of MCL biology and outline our recommended approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted therapies, on the basis of a synthesis of the data from published clinical trials.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Epidemiology, Diagnosis & Staging, Chemotherapy, Biologic Therapy, Biology & Immunology, Translational Oncology REVIEW ARTICLE Source Type: research

Related Links:

AbstractAutologous stem cell transplant (ASCT) is an effective treatment for non-Hodgkin lymphoma (NHL). However, recent supply issues and toxicity of carmustine have necessitated a new conditioning regimen. We conducted a multicenter, phase II study of BEB (busulfan, etoposide, and bendamustine) conditioning regimen for ASCT in patients with NHL. Thirty-one patients were enrolled and underwent ASCT with the BEB conditioning regimen. The most common subtype was diffuse large B-cell lymphoma (n = 23, 74.2%). Nine patients (29.0%) had a history of relapse, and 18 patients (58.1%) received more than 2 lines of c...
Source: Annals of Hematology - Category: Hematology Source Type: research
Mainstay treatment options for patients with relapsed or refractory Hodgkin's lymphoma and Non-Hodgkin's lymphoma (NHL) include high dose chemotherapy and autologous stem cell transplantation (aSCT). Several chemotherapy regimens have been explored with various drug combinations. To date, no objective data is available to indicate that one particular regimen is better than another in regards to superiority. When selecting one regimen compared to another, the choice will depend on each institution's individual practices, guidelines, and toxicities associated with each regimen.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 626 Source Type: research
High dose chemotherapy followed by autologous stem cell transplantation (ASCT) offers a cure in the relapsed setting in both Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Additionally, it remains a first-line standard of care in multiple myeloma (MM) patients whom are eligible for ASCT. However, the management of these hematologic malignancies continues to rapidly evolve with non-cytotoxic therapeutic options such as development of new cellular therapies. These developments underscore the importance of monitoring immune reconstitution after ASCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 476 Source Type: research
Conclusions: Salvage chemotherapy (often with rituximab and radiotherapy), followed by HDT and stem cell transplantation, appears to be the standard real-world treatment for rrPMBCL. However, large prospective and retrospective studies are warranted to improve our knowledge of real-world treatment patterns. PMID: 31951774 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Conditions:   Recurrent Aggressive Non-Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent High Grade B-Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Recurrent Transformed B-Cell  Non-Hodgkin Lymphoma Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophospham...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONThe findings highlight a significant burden associated with CDI in haematological patients undergoing induction chemotherapy in the US. There is an important need for prevention of CDI in this specific patient population.
Source: Journal of Hospital Infection - Category: Infectious Diseases Source Type: research
Authors: Ruan J Abstract Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) translocation leading to cyclin D1 overexpression and cell cycle dysregulation. Molecular profiling with gene expression and deep sequencing analyses has identified genomic and epigenomic alterations in pathways regulating the cell cycle, DNA damage response, proliferation, and survival, which contribute to disease progression with important prognostic and therapeutic implications. Clinically, the nonnodal MCL subset is notable for leukemic presentation, indolent behavior, ...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
CONCLUSIONS This retrospective study based on real-world data introduces the option of substituting carmustine with cisplatin+dexamethasone, with a similar response, expected lower cost, and better accessibility in developing nations. PMID: 31636248 [PubMed - in process]
Source: Annals of Transplantation - Category: Transplant Surgery Authors: Tags: Ann Transplant Source Type: research
Non-Hodgkin lymphoma (NHL) is typically sensitive to conventional doses of chemotherapy but many patients do not respond to front-line treatment or subsequently relapse after achieving remission. For medically-fit patients with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), subsequent treatment with high dose chemotherapy and autologous hematopoietic stem cell transplantation (ASCT) is often indicated [1 –4]. ASCT is also performed as consolidation treatment for patients with mantle cell lymphoma (MCL) and peripheral T-cell lymphoma (PTCL) and is associated with favorable progr...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Allergy & Immunology | Biology | Cancer & Oncology | Chemotherapy | Clinical Trials | Epidemiology | Food and Drug Administration (FDA) | Lymphoma | Molecular Biology | Non-Hodgkin's Lymphoma | Revlimid | Rituxan | Stem Cell Therapy | Stem Cells | Transplants | Treanda | Velcade